Sabiad

Sabiad is a spin-off from the University Medical Center Groningen that develops theranostic solutions for the detection and treatment of Staphylococcus aureus infections. The company utilizes its patented StaphMark technology and the 1D9 antibody to provide real-time precision imaging and targeted therapy, specifically designed to disrupt biofilms in surgical and orthopedic settings. Their products serve infectious disease specialists and orthopedic surgeons to reduce reliance on broad-spectrum antibiotics and improve patient outcomes in joint replacements and fracture repairs.